Introduction
The CDC’s Advisory Committee on Immunization Practices (ACIP) serves a critical role in formulating recommendations that guide national immunization strategies. These recommendations directly affect individual healthcare decisions, shape public health outcomes, and influence the financial and logistical planning of healthcare providers and vaccine manufacturers.
Vaccines, particularly pneumonia vaccines, are essential tools in the prevention of life-threatening illnesses. They reduce healthcare costs, prevent long-term complications, and save lives by protecting individuals from diseases like pneumococcal pneumonia. While the current routine ACIP recommendation for the adult pneumonia vaccination begins at age 65, in addition to those age 19 – 64 who are deemed “at-risk”, there is mounting evidence to support lowering the routine age-based recommendation to 50. This proactive public health policy would provide earlier protection, especially for at-risk groups, and would reduce preventable deaths and healthcare costs.
This paper advocates for ACIP to lower the age-based routine recommendation for pneumococcal vaccines to 50 while supporting the use of all available vaccines—to ensure comprehensive protection and maintain supply chain resilience. Furthermore, it underscores the importance of fostering innovation in the vaccine market by avoiding sole-source contracts or preferring one vaccine over another based on cost-effectiveness analyses.
READ WHITE PAPER HERE
